Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:Qualitest_Pharmaceuticals
gptkb:Qualitest_Pharmaceuticals,_Inc. gptkb:Par_Pharmaceutical_Companies,_Inc. Par Pharmaceutical AstraZeneca's_rights_to_the_drug_Testim. AstraZeneca's_rights_to_the_drug_Vasostrict. Bristol-Myers_Squibb's_Opioid_Business Bristol-Myers_Squibb's_rights_to_the_drug_Opana. Dava_Pharmaceuticals. Par_Pharmaceutical's_generic_drugs. |
| gptkbp:CEO |
gptkb:Paul_Campanelli
|
| gptkbp:employs |
approximately 3,000 people
|
| gptkbp:focusesOn |
endocrinology
pain management urology |
| gptkbp:founded |
1997
|
| gptkbp:hasProductLine |
Opana ER
Percocet Vasostrict Testim |
| gptkbp:hasSubsidiary |
gptkb:Endo_International_plc
gptkb:Endo_Pharmaceuticals_Inc. |
| gptkbp:headquarters |
gptkb:Malvern,_Pennsylvania
|
| https://www.w3.org/2000/01/rdf-schema#label |
Endo Health Solutions
|
| gptkbp:market |
Chronic pain management.
Hormonal therapies. Specialty pharmaceuticals. Urological conditions. Generic_medications. |
| gptkbp:operatesIn |
gptkb:Canada
gptkb:United_States Europe |
| gptkbp:partnerships |
Research institutions.
Various healthcare organizations. Patient advocacy groups. Healthcare_providers. |
| gptkbp:philanthropy |
Research funding.
Community health initiatives. Educational grants. Patient assistance programs. Endo_Foundation. |
| gptkbp:regulatoryCompliance |
Product recalls.
Litigation related to opioid products. Settlement agreements. Compliance_with_DEA_regulations. FDA_warnings. |
| gptkbp:revenue |
$2.5 billion (2020)
|
| gptkbp:stockSymbol |
ENDP
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:website |
www.endo.com
|